SK bioscience Co.,Ltd.
Korea ExchangeTotal Valuation
SK bioscience Co.,Ltd. carries a market capitalization of 2.95T, placing it among publicly traded companies globally. Its enterprise value stands at 3.17T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.95T |
| Enterprise Value | 3.17T |
Share Statistics
SK bioscience Co.,Ltd. currently has 78.43M shares outstanding.
| Shares Outstanding | 78.43M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 4.91, and the price-to-book ratio stands at 7.24.
| PE Ratio | N/A |
| PS Ratio | 4.91 |
| PB Ratio | 7.24 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | 11.86 |
| P/OCF Ratio | -1,179.31 |
Enterprise Valuation
| EV / Sales | 4.76 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 11.18 |
Financial Position
SK bioscience Co.,Ltd. maintains a current ratio of 4.04, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.59, indicating elevated leverage, while an interest coverage ratio of -14.28 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.04 |
| Quick Ratio | 2.87 |
| Debt / Equity | 26.59 |
| Debt / EBITDA | -3.52 |
| Interest Coverage | -14.28 |
Financial Efficiency
| Return on Equity (ROE) | -16.95 |
| Return on Assets (ROA) | -2.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.96 |
Taxes
| Income Tax | -31.64B |
| Effective Tax Rate | N/A |
Stock Price Statistics
SK bioscience Co.,Ltd.'s stock has declined approximately -22.15321% over the past 52 weeks. The 50-day moving average sits at 40,424.00, while the 200-day moving average is 46,584.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | -22.15321% |
| 50-Day Moving Average | 40,424.00 |
| 200-Day Moving Average | 46,584.75 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, SK bioscience Co.,Ltd. generated 665.42B in revenue and converted that into -83.29B in net income, yielding earnings per share of -1,126.89. EBITDA reached -152.91B, while operating income came in at -152.91B.
| Revenue | 665.42B |
| Gross Profit | 64.65B |
| Operating Income | -152.91B |
| Pretax Income | -119.90B |
| Net Income | -83.29B |
| EBITDA | -152.91B |
| EBIT | -152.91B |
| Earnings Per Share (EPS) | -1,126.89 |
Balance Sheet
SK bioscience Co.,Ltd. holds 890.16B in cash and equivalents against 538.00B in total debt, resulting in a net debt position of 447.49B. Total book value stands at 451.16B, with working capital of 943.61B providing operational flexibility.
| Cash & Cash Equivalents | 890.16B |
| Total Debt | 538.00B |
| Net Debt | 447.49B |
| Equity (Book Value) | 451.16B |
| Book Value Per Share | 5,759.98 |
| Working Capital | 943.61B |
Cash Flow
SK bioscience Co.,Ltd. produced -2.77B in operating cash flow over the past twelve months. After subtracting -278.18B in capital expenditures, free cash flow totaled -280.95B - equivalent to -3,586.83 per share.
| Operating Cash Flow | -2.77B |
| Capital Expenditures | -278.18B |
| Free Cash Flow | -280.95B |
| FCF Per Share | -3,586.83 |
Margins
SK bioscience Co.,Ltd. operates with a gross margin of 9.72, reflecting its pricing power and cost economics. The operating margin of -22.98 and net profit margin of -12.52 provide insight into operational efficiency.
| Gross Margin | 9.72 |
| Operating Margin | -22.98 |
| Pretax Margin | -18.02 |
| Profit Margin | -12.52 |
| EBITDA Margin | -22.98 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.11 |
| FCF Yield | 8.43 |
Scores
SK bioscience Co.,Ltd. posts an Altman Z-Score of 2.70, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.70 |